Evonik's Strategic Overhaul Takes Definitive Shape with New Financial Framework

Evonik's 2025 results show a sales decline but meet EBITDA targets. The firm announces a new flexible dividend policy, a 10% price increase for MetAMINO®, and nears the end of its major restructuring.

The German specialty chemicals group Evonik has released its 2025 annual results, marking a pivotal moment in its corporate transformation. The figures not only met key forecasts but were accompanied by a series of strategic decisions that redefine the company's future trajectory. These moves include a revised sales outlook, a significant price increase for a core product, and a fundamental shift in its approach to shareholder returns, signaling the final phase of a major restructuring effort.

Financial Performance and Revised Guidance

For the fiscal year 2025, Evonik reported a 7% decline in sales, which totaled €14.1 billion. Its adjusted EBITDA came in at €1.87 billion, aligning with the projected figure of approximately €1.9 billion. The company's cash conversion rate reached 37%, hitting the upper end of its target range. Net income showed improvement, climbing to €265 million from €222 million the previous year.

Looking ahead to 2026, management has reaffirmed its adjusted EBITDA guidance, maintaining a target range of €1.7 to €2.0 billion. However, the sales forecast has been narrowed and adjusted downward. Evonik now anticipates revenue between €13.5 and €14.5 billion, a revision that reflects persistent challenges in certain business areas. The medium-term strategic focus remains fixed on achieving an 11% return on capital employed.

Strategic Pricing Move for Key Product

In a decisive step to bolster profitability, Evonik has implemented an immediate 10% net price increase for its flagship product MetAMINO® (DL-Methionine 99%, feed grade). This adjustment applies globally across all markets, though existing contracts will be honored. The initiative is designed to stabilize margins in an operating environment where volume growth is becoming increasingly difficult to secure.

MetAMINO® falls within the Advanced Technologies segment, which also encompasses high-performance polymers, hydrogen peroxide, and silica. This division, which includes the animal nutrition business, generated €5.9 billion in revenue during 2025.

A More Flexible Dividend Policy

Beginning in 2026, Evonik will adopt a new, more flexible dividend policy. The company intends to distribute between 40% and 60% of its adjusted net income annually, a clear departure from its previous commitment to a consistent payout. As a transitional measure for 2025, the board has proposed a dividend of €1.00 per share, down from €1.17 per share the year before. Shareholders will vote on this proposal at the Annual General Meeting scheduled for June 3, 2026.

Transformation Program Nears Completion

The comprehensive "Evonik Tailor Made" transformation program is on track for completion in 2026. Upon finalization, it is expected to yield annual cost savings of approximately €400 million. Roughly 80% of these savings, or around €320 million, are tied to workforce reductions. The plan involves cutting up to 2,000 positions worldwide, with approximately 1,500 of those jobs located in Germany.

Since April 2025, Evonik has operated under a streamlined two-segment structure: "Custom Solutions" and "Advanced Technologies," each with annual sales of around €6 billion. This reorganization aims to accelerate decision-making processes across the corporation.

A notable point of ongoing attention, both internally and externally, remains the vacant position on the executive board for the Chief Financial Officer. The market will gain further insight into the company's progress with the release of first-quarter 2026 results on May 8.